**Research Article**

**Risk Factors for Failure of Direct Current Cardioversion in Patients with Type 2 Diabetes Mellitus and Atrial Fibrillation**

Handrean Soran,1,2 Moulinath Banerjee,3 Jamal B. Mohamad,4 Safwaan Adam,1,2 Jan Hoong Ho,1,2 Shakawan M. Ismaeel,5 Shaishav Dhage,2 Akheel A. Syed,2,6 Ibrahem M. A. Abdulla,7 Naveed Younis,8 and Rayaz A. Malik2,9

1Cardiovascular Trials Unit, The Old St Mary’s Hospital, Hathersage Road, Manchester, UK
2Cardiovascular Research Group, Core Technology Facility, University of Manchester, 3rd Floor, 46 Grafton Street, Manchester, UK
3Bolton Diabetes and Endocrine Unit, Royal Bolton Hospital, Bolton, UK
4Department of Medicine, School of Medicine, Duhok University, Duhok, Kurdistan Region, Iraq
5Department of Medicine, Wirral University Teaching Hospital, Wirral, UK
6Department of Endocrinology, Salford Royal Hospital, Salford, UK
7Department of Medicine, Shar Hospital, Salaymantiyah, Kurdistan Region, Iraq
8Department of Diabetes and Endocrinology, University Hospital of South Manchester, Manchester, UK
9Weill Cornell Medical College Qatar, Division of Medicine, Qatar Foundation, Education City, Doha, Qatar

Correspondence should be addressed to Handrean Soran; hsoran@aol.com

Received 22 June 2017; Revised 3 December 2017; Accepted 8 February 2018; Published 12 March 2018

1. Introduction

Type 2 diabetes mellitus (T2DM) is a well-recognised risk factor for cardiovascular disease and the prevalence of atrial fibrillation (AF) is higher among patients with T2DM. Direct current cardioversion (DCCV) is an important management option in persistent AF. We sought to determine independent risk factors for immediate and short-term outcomes of DCCV for treatment of AF in patients with T2DM. Methods. Retrospective outcome analysis of DCCV for persistent AF in 102 T2DM patients compared with 102 controls. Results. DCCV was successful in 68 (66.6%) people with T2DM compared to 86 (84.3%) in the control group ($P = 0.003$). After initial successful cardioversion, only 38 (37.2%) T2DM patients remained in sinus rhythm compared to 63 (61.8%) in the control group ($P = 0.007$) at a median follow-up of 74.5 days (IQR 69.4–77.4). Multiple logistic regression analysis showed that the presence of T2DM ($P = 0.014$), digoxin use ($P = 0.01$), statin use ($P = 0.005$), left-atrial size ($P = 0.01$), and LV ejection fraction ($P = 0.008$) were independent risk factors for immediate DCCV failure. T2DM ($P = 0.034$) was an independent risk factor for AF relapse. Among patients with T2DM, previous DCCV ($P = 0.033$), digoxin use ($P = 0.035$), left-atrial size ($P = 0.01$), LV ejection fraction ($P = 0.036$), and HbA1c ($P = 0.011$) predicted immediate failure of DCCV whilst digoxin use ($P = 0.026$) was an independent risk factor for relapse of AF. Conclusion. T2DM, higher HbA1c, digoxin treatment, and structural and functional cardiac abnormalities are independent risk factors for immediate DCCV failure and AF relapse.
Patients with cardiac valvular disease included. Those who underwent DCCV from October 2001 to April 2007 were included.

Inclusion Criteria. All adult patients with documented pAF who underwent DCCV from October 2001 to April 2007 were included.

Exclusion Criteria. Patients with cardiac valvular disease (other than mild mitral and tricuspid valve regurgitation), rheumatic heart disease, previous heart valve surgery, congenital heart disease, patients with AF as a consequence of acute myocardial infarction (MI) or cardiac surgery, significant chronic kidney disease (defined as eGFR less than 60 ml/min/1.73 m$^2$), AF secondary to thyrotoxicosis, patients who reverted to sinus rhythm (SR) before DCCV, and patients in whom relevant data were missing from the notes were excluded from the study. A total of 45 patients were excluded: 14 had valvular heart disease, two had history of heart valve replacement, three had AF after coronary artery bypass grafting, eight reverted to SR before attempted DCCV, two had AF secondary to thyrotoxicosis, five developed AF in the course of acute MI, and 13 were excluded because of missing data (Figure 1).

Of the 364 eligible patients, 102 had T2DM and of the 262 patients without T2DM 102 age and gender matched patients were selected as the control group for this study (Table 1).

All patients were anticoagulated for at least 6 weeks prior to cardioversion. International normalized ratio (INR) was checked at least weekly for the preceding 4 weeks prior to cardioversion and the dose of warfarin was adjusted to maintain the INR between 2.0 and 3.0 (target INR 2.5). Digoxin was stopped in all patients 48 hours before cardioversion and not recommenced in patients who had successful DCCV. Thyroid function tests, urea and electrolytes, full blood count, and cholesterol were checked in all patients. If amiodarone, sotalol, or flecainide were prescribed, patients continued on these until reviewed in clinic. All patients were reviewed 3 to 4 hours after DCCV (prior to discharge) and subsequently in the outpatient clinic. Clinical examination and a 12-lead electrocardiogram (ECG) were performed at each review.

Successful DCCV was defined by an ECG 3 hours after DCCV showing sinus rhythm. Persistent AF was defined as episodes that failed to self-terminate spontaneously and lasted for longer than 7 days but could be converted to SR with pharmacological or electrical cardioversion. The duration of AF was the period (in weeks) from the first day of diagnosis of the index atrial fibrillation supported by ECG to the day of DCCV. In patients who had a successful cardioversion, the arrhythmia status on the day of first outpatient follow-up was documented to assess differences between the two groups. All patients with a documented history of hypertension or three recent blood pressure readings greater than 160/90 mmHg were regarded as having hypertension. All patients on lipid-lowering treatment or with a total serum cholesterol measurement greater than 5.2 mmol/l were regarded as having hyperlipidaemia. In patients with diabetes, a mean HbA1c of the three most recent measurements was used. HbA1c values were measured by affinity chromatography using a commercial kit (BioRad, UK; nondiabetic range 22–40 mmol/mol [4.2–5.8%]). Echocardiograms were performed in the Department of Cardiology, Wirral University Hospitals NHS Foundation Trust (using Philips-Sonos 5500 and Philips-Sonos 5400). All echocardiogram operators had British Society of Echocardiography accreditation. An estimate of left ventricular ejection fraction (LVEF) was made using automated software. Left ventricular hypertrophy (LVH) was diagnosed using echocardiography by measuring the thickness of the intraventricular septum and posterior wall. Using an anteroapical position, monophasic DCCV was performed on an elective basis with a Hewlett Packard device. One hundred joules was used as the initial energy current and titrated according to response to a maximum of 360 J.

Statistical analysis SPSS v22.0 was used to analyse the data. Data were expressed as frequency and percentage for categorical data and mean ± SD for continuous data. We used recurrence of AF at the first outpatient follow-up as the dependent outcome. Univariate model with a cut-off of
Preexisting atherosclerotic disease, dyslipidaemia, alcohol excess, use of statins, RAS inhibitor usage, any heart-rate limiting agent usage, and presence of LVH, T2DM (β: –0.144, 95% CI of β: –0.259 to –0.029, \( P = 0.014 \)), use of digoxin (β: –0.162, 95% CI of β: –0.285 to –0.040, and \( P = 0.01 \)), statin use (β: –0.204, 95% CI of β: –0.347 to –0.062, and \( P = 0.005 \)), left-atrial size (β: –0.103, 95% CI of β: –0.181 to –0.025, and \( P = 0.01 \)), and LVEF (β: 0.006, 95% CI of β: 0.002 to 0.011, and \( P = 0.008 \)) independently influenced attainment of SR immediately after DCCV (Table 2). A further model which also included the time between DCCV and the first follow-up visit as well as the aforementioned factors found T2DM (β: –0.186, 95% CI of β: –0.357 to –0.014, and \( P = 0.034 \)) to independently and inversely influence the persistence of SR at the 1st visit following DCCV.

In patients with T2DM, after adjusting for age, gender, duration of AF, smoking history, preexisting atherosclerotic disease, dyslipidaemia, alcohol excess, use of statins, RAS inhibitors, and rate limiting agents, T2DM, type 2 diabetes mellitus.

### Table 1: Baseline characteristics of patients. Data are mean (SD). AF, atrial fibrillation; DC, direct current; CAD, coronary artery disease; PAD, peripheral arterial disease; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; LA, left atrium; LV, left ventricle.

| Characteristics                      | Patients without T2DM (n = 102) | Patients with T2DM (n = 102) | \( P \) |
|--------------------------------------|---------------------------------|-------------------------------|--------|
| Age, years                           | 69.4 ± 7.8                      | 68.9 ± 7.6                    | NS     |
| Gender ratio, M : F                  | 0.73                            | 0.73                          | NS     |
| Duration of AF prior to DC cardioversion, weeks | 14.7 ± 8.8                      | 20.3 ± 18.8                   | 0.007  |
| Previous DC cardioversion, n (%)     | 6 (5.9)                         | 3 (2.9)                       | NS     |
| History of smoking, n (%)            | 2 (2.0)                         | 8 (7.8)                       | 0.052  |
| Preexisting atherosclerotic disease (CAD, stroke, and PAD), n (%) | 45 (44.1)                        | 50 (49.0)                     | NS     |
| Obstructive airways diseases, n (%)  | 11 (10.8)                       | 8 (7.8)                       | NS     |
| Hyperlipidaemia, n (%)               | 36 (35.3)                       | 42 (41.2)                     | NS     |
| History of alcohol excess, n (%)     | 4 (3.9)                         | 2 (2.0)                       | NS     |
| ACE-inhibitor or ARB use, n (%)      | 40 (39.2)                       | 63 (61.8)                     | 0.001  |
| Amiodarone use, n (%)                | 46 (45.1)                       | 40 (39.2)                     | NS     |
| Flecaïnide use, n (%)                | 1 (1.0)                         | 2 (2.0)                       | NS     |
| Sotalol use, n (%)                   | 4 (3.9)                         | 4 (3.9)                       | NS     |
| Beta-blocker use, n (%)              | 33 (32.4)                       | 27 (26.5)                     | NS     |
| Calcium channel blocker use, n (%)   | 23 (22.5)                       | 33 (32.4)                     | NS     |
| Digoxin use, n (%)                   | 29 (28.4)                       | 36 (35.3)                     | NS     |
| Statin use, n (%)                    | 29 (28.4)                       | 32 (31.4)                     | NS     |
| LA size, cm                         | 4.3 ± 0.8                       | 4.3 ± 0.7                     | NS     |
| LV ejection fraction, %              | 56.2 ± 11.8                     | 54.0 ± 12.4                   | NS     |
| Presence of LV hypertrophy, %        | 14 (13.7)                       | 10 (9.8)                      | NS     |
| 1st follow-up visit after DC cardioversion, days | 75.2 ± 6.9                     | 74.9 ± 7.5                    | NS     |

\( P < 0.05 \) was used to identify potentially significant factors. Multiple regression analyses using the factors identified above were used to identify independent risk factors for recurrence of AF following successful DC cardioversion. A \( P \) value < 0.05 was statistically significant.

### Table 2: Regression model assessing factors affecting attainment of sinus rhythm immediately after DCCV. DCCV, direct current cardioversion; LA, left atrium; LVEF, left ventricular ejection fraction; T2DM, type 2 diabetes mellitus.

| Variables             | \( \beta \)-Coefficient | \( P \) |
|-----------------------|--------------------------|--------|
| T2DM                  | –0.144                   | 0.014  |
| Digoxin use           | –0.162                   | 0.010  |
| Statin use            | –0.204                   | 0.005  |
| LA size               | –0.103                   | 0.010  |
| LVEF                  | 0.006                    | 0.008  |

### 3. Results

102 patients with T2DM with a mean diabetes duration of 5.5 (95% CI: 4.6–6.4) years and 102 age and gender matched control patients without T2DM underwent DCCV for nonvalvular AF (Table 1). Apart from the duration of AF prior to DCCV and use of renin angiotensin system (RAS) inhibitors, there were no significant differences between the two groups.

DCCV resulted in immediate (prehospital discharge) success in 75.5% of all patients. Of the 102 patients with T2DM, 68 (66.6%) achieved immediate cardioversion to sinus rhythm compared to 86 (84.3%) of 102 patients without T2DM (OR: 0.372, 95% CI: 1.89–0.73, and \( P = 0.003 \)). The median time to the 1st follow-up visit was 75 [95% CI: 74.0–76.0] days; of the 68 patients with T2DM who had achieved immediately successful DCCV, 38 (55.9%) had maintained sinus rhythm compared to 63 of 86 (73.3%) patients without T2DM [OR: 0.398, 95% CI: 0.203–0.730, and \( P = 0.007 \)] (Figure 2).

#### 3.1. Multiple Regression Analysis

After adjusting for age, gender, duration of AF, previous DCCV, smoking history, preexisting atherosclerotic disease, dyslipidaemia, alcohol excess, use of statins, RAS inhibitors, and rate limiting agents,
Table 3: Regression model assessing factors affecting attainment of sinus rhythm immediately after DCCV in patients with T2DM. DCCV, direct current cardioversion; HbA1c, glycated haemoglobin; LA, left atrium; LVEF, left ventricular ejection fraction; T2DM, type 2 diabetes mellitus.

| Variables | $\beta$-Coefficient | $P$ |
|-----------|----------------------|-----|
| Previous DCCV | $-0.558$ | $0.033$ |
| Digoxin use | $-0.206$ | $0.035$ |
| LA size | $-0.184$ | $0.010$ |
| LVEF | $0.007$ | $0.036$ |
| HbA1c | $-0.104$ | $0.011$ |

Conceptually, consequences of AF can be mostly ameliorated by attainment of sinus rhythm, though this has been debated [11]. When chemical cardioversion fails electrical cardioversion may be attempted depending on physician and patient preference [6]. In the present study the overall immediate prehospital discharge success rate of DCCV in our patients was 75.5%, which is comparable to previous reports [12]. Possible reasons for failure to attain and maintain sinus rhythm have been discussed by Frick et al. [12], but their list does not include diabetes. Indeed, there are very limited data regarding success rate of DC cardioversion in patients with diabetes. Thus in a small cohort of 48 patients, where the efficacy of atorvastatin in preventing the recurrence of AF was investigated, diabetes was found to be a significant risk factor influencing the risk of recurrence of AF [13].

We demonstrate, for the first time, a lower success rate of both immediate cardioversion and subsequent maintenance of sinus rhythm in patients with T2DM. Indeed, further regression analysis confirmed that the diagnoses of T2DM and HbA1c among the patients with T2DM are independent risk factors for DC cardioversion failure. Poorer glycaemic control is a known risk factor for CVD [1] and the risk of developing atrial fibrillation [14]. Furthermore, patients with diabetes and AF are more likely to develop cardioembolic stroke [15], as well as having increased morbidity and mortality [16]. It is therefore postulated that limiting the onset of AF and reversion to sinus rhythm may result in improved outcomes [14], although more conclusive evidence for this is required. Improved glycaemic control per se was not shown to impact on the incidence of atrial fibrillation in the recent ACCORD study [16]. A recent study has shown that a higher HbA1c is associated with an increased risk of recurrence of atrial tachyarrhythmia in patients with T2DM undergoing catheter ablation [17]. However, the impact of T2DM and especially the impact of hyperglycaemia on the success of DCCV have not been described to date.

The presence of other microvascular and macrovascular complications may directly influence the development and chronicity of atrial fibrillation in people with diabetes [18]. Indeed, the prevalence of AF was shown to be greater in patients with diabetic autonomic neuropathy compared with patients who have diabetes but without neuropathy [19]. Importantly, cardiac autonomic neuropathy can influence the onset of AF as well as prognosis following DCCV [20]. After adjustment for preexisting macrovascular and microvascular disease, HbA1c remained an independent adverse risk factor for the success of DCCV. Recurrent AF has a low success rate of cardioversion which is secondary to atrial remodeling during AF [21]. This in itself was found to be an independent risk factor for unsuccessful treatment of AF in patients with T2DM.

It is well known that patients treated with digoxin have a lower chance of spontaneous reversions to sinus rhythm, as well as successful DCCV [22]. In this study we show a similar result, particularly in patients with T2DM. In this group it was found to be an independent risk factor influencing the immediate success as well as maintenance of sinus rhythm.
at follow-up. Why digoxin use may influence more adverse outcomes is not clear, but altered myocardial calcium homeostasis in patients with T2DM may be a possible explanation [23].

Statins have also been shown to have a favourable impact on attaining and maintaining sinus rhythm in patients with AF [13]. However, we found that concomitant statin usage had a favourable impact on the whole group, but not among the patients with T2DM. This may be due to the myocardial electrophysiological effect of statins which could be mediated by a reduction in CRP [24], interleukins [25], catecholamines [26], and altered cell membrane properties [27], which may well be further attenuated in patients with T2DM.

Structural cardiac alteration with increased LA size [28] in particular is known to influence success in maintaining sinus rhythm in patients undergoing DC cardioversion for AF. Thus AF per se is thought to lead to left-atrial remodeling [28]. We confirm this association in patients with and without T2DM. The other major haemodynamic consequence of persistent AF is its impact on LV systolic function, which can improve after reversion to sinus rhythm [29]. The main mechanism for such a reduction may be the tachycardia-induced LV systolic dysfunction, due to reduced myocardial calcium secondary to shortened diastole [30].

The present study is the largest case-control study identifying a range of risk factors, determining immediate and longer-term outcomes following DC cardioversion in patients with T2DM. A limitation of this study is that the technique for cardioversion used was monophasic DCCV whilst current clinical guidelines advocate the use of biphasic DCCV due to superior efficacy and fewer energy requirements [6]. The success rate for DCCV at the first visit in our study as aforementioned was similar to previous reports [12] and interestingly for patients without T2DM the proportion of those who attained sinus rhythm was 84% which is very similar to the results in a previous relatively large study in which the efficacy of monophasic DCCV was found to be inferior to biphasic DCCV (84% versus 95% success rate) [31]. In that study, out of the 229 patients who had monophasic DCCV for treatment of AF, only 9 had a history of diabetes [31]. Another limitation of this study was that the duration of AF precadioversion was significantly longer in the group of patients with T2DM compared to those without T2DM. Duration of AF is known to be a risk factor for inability to achieve sinus rhythm on first attempt as well as recurrence of AF at follow-up using DCCV treatment [12]. Duration of AF was therefore adjusted in the regression model when determining independent risk factors for both immediate success and relapse. Ventricular rate prior to DCCV was not assessed as a significant proportion of patients were on rate limiting medications. The prevalence of rate limiting medication use, however, did not differ between groups with and without T2DM. We acknowledge that due to the retrospective design of this study certain relevant information such as body mass index was not readily available to us and would have added to the data interpretation. Despite consideration of all of these factors, we believe this study provides important insights into the potential basis for poorer outcomes in patients with T2DM undergoing DCCV.

5. Conclusion

The presence of T2DM and the degree of hyperglycaemia as represented by HbA1c are independent risk factors for immediate and medium-term failure of DCCV in patients with AF.

Additional Points

Key Messages. (i) This study shows that type 2 diabetes negatively impacts on the success of direct current cardioversion (DCCV) for atrial fibrillation (AF). (ii) The presence of T2DM is an independent risk factor for the relapse of AF after treatment. (iii) We report that in patients with type 2 diabetes glycated haemoglobin is a predictor for immediate DCCV failure in AF.

Conflicts of Interest

Handrean Soran received research grants from Synageva, Pfizer, Amgen, and MSD and honoraria from Sanofi, Synageva, BMS, Lilly, AstraZeneca, Pfizer, Takeda, AMGEN, and MSD. Naveed Younis received research grants from Sanofi and honoraria from Jansen, Astra-Zeneca, Lilly, and Novo-Nordisk. Moulinath Banerjee, Safwaan Adam, Shakawaw M. Ismaeel, Jan Hoong Ho, Akheel A. Syed, and Rayaz A. Malik have no conflicts of interest to declare.

Acknowledgments

The authors acknowledge support from Lipid Disease Fund and the National Institute for Health Research/Wellcome Trust Clinical Research Facility.

References

[1] I. M. Stratton, A. I. Adler, H. A. W. Neil et al., “Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study,” British Medical Journal, vol. 321, no. 7258, pp. 405–412, 2000.
[2] P. G. Carnici and F. Crea, “Coronary microvascular dysfunction,” The New England Journal of Medicine, vol. 356, no. 8, pp. 830–840, 2007.
[3] E. J. Benjamin, D. Levy, S. M. Vaziri, R. B. D’Agostino, A. J. Belanger, and P. A. Wolf, “Independent risk factors for atrial fibrillation in a population-based Cohort: the Framingham heart study,” Journal of the American Medical Association, vol. 271, no. 11, pp. 840–844, 1994.
[4] M.-R. Movahed, M. Hashemzadeh, and M. Mazen Jamal, “Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease,” International Journal of Cardiology, vol. 105, no. 3, pp. 315–318, 2005.
[5] M. E. Cain, “Atrial fibrillation - Rhythm or rate control,” The New England Journal of Medicine, vol. 347, no. 23, pp. 1822-1823, 2002.
[6] P. Kirchhof, S. Benussi, D. Kotecha et al., “2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European
Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO), European Heart Journal, vol. 37, no. 38, pp. 2893–2962, 2016.

[7] J. L. Pallisgaard, T. B. Lindhardt, J. B. Olesen, M. L. Hansen, N. Carlson, and G. H. Gislason, “Management and prognosis of atrial fibrillation in the diabetic patient,” Expert Review of Cardiovascular Therapy, vol. 13, no. 6, pp. 643–651, 2015.

[8] G. Novo, D. Guttilla, G. Fazio, D. Cooper, and S. Novo, “The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBs,” British Journal of Clinical Pharmacology, vol. 66, no. 3, pp. 345–351, 2008.

[9] F. Najji, D. Suran, V. Kanic, D. Vokac, and M. Sabovic, “Comparison of atorvastatin and simvastatin in prevention of atrial fibrillation after successful cardioversion,” International Heart Journal, vol. 50, no. 2, pp. 153–160, 2009.

[10] H. Soran, N. Younis, P. Currie, J. R. Jones, and G. Gill, “Influence of diabetes on the maintenance of sinus rhythm after a successful direct current cardioversion in patients with atrial fibrillation,” QJM: An International Journal of Medicine, vol. 101, no. 3, pp. 181–187, 2008.

[11] V. E. Hagens, A. V. Ranchor, E. Van Sonderen et al., “Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: Results from the rate control versus electrical cardioversion (RACE) study,” Journal of the American College of Cardiology, vol. 43, no. 2, pp. 241–247, 2004.

[12] M. Frick, V. Frykman, M. Jensen-Urstad, J. Østergren, and M. Rosenqvist, “Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation,” Clinical Cardiology, vol. 24, no. 3, pp. 238–244, 2001.

[13] M. Ozaydin, E. Varol, S. M. Aslan et al., “Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion,” American Journal of Cardiology, vol. 97, no. 10, pp. 1490–1493, 2006.

[14] O. Asghar, U. Alam, S. A. Hayat, A. Aghamohammadzadeh, A. M. Heagerty, and R. A. Malik, “Obesity, diabetes and atrial fibrillation: epidemiology, mechanisms and interventions,” Current Cardiology Reviews, vol. 8, no. 4, pp. 253–264, 2012.

[15] W. Saliba, O. Barnett-Griness, M. Elias, and G. Rennert, “Glycated hemoglobin and risk of first episode stroke in diabetic patients with atrial fibrillation: A cohort study,” Heart Rhythm, vol. 12, no. 5, article no. 6096, pp. 886–892, 2015.

[16] O. Fatemi, E. Yuriditsky, C. Tsiofis et al., “Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the action to control cardiovascular risk in diabetes study),” American Journal of Cardiology, vol. 114, no. 8, pp. 1217–1222, 2014.

[17] Z.-H. Lu, N. Liu, R. Bai et al., “HbA1c levels as predictors of ablation outcome in type 2 diabetes mellitus and paroxysmal atrial fibrillation,” Herz, vol. 40, no. 2, pp. 130–136, 2015.

[18] M. F. Di Carlo, J. Janisse, G. Grunberger, and J. Ager, “Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes,” Journal of the American College of Cardiology, vol. 41, no. 8, pp. 1387–1393, 2003.

[19] I. G. Yağız, S. Bayata, M. Yeşil, T. K. I. İncesi, E. Arikan, and N. Postaci, “Prevalence and clinical features of atrial fibrillation in diabetic neuropathy: A cross-sectional, observational study,” Anadolu Kardiyoloji Dergisi, vol. 12, no. 8, pp. 646–651, 2012.

[20] H. Otake, H. Suzuki, T. Honda, and Y. Maruyama, “Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart,” International Heart Journal, vol. 50, no. 5, pp. 627–641, 2009.

[21] R. G. Tieleman, I. C. Van Gelder, H. J. G. M. Crijns et al., “Early recurrences of atrial fibrillation after electrical cardioversion: A results of fibrillation-induced electrical remodeling of the atria?,” Journal of the American College of Cardiology, vol. 31, no. 1, pp. 167–173, 1998.

[22] M. Ehle, C. Patel, and R. P. Giugliano, “Digoxin: Clinical highlights: A review of digoxin and Its use in contemporary medicine,” Critical Pathways in Cardiology, vol. 10, no. 2, pp. 93–98, 2011.

[23] R. Harmancye and H. Taegteymer, “The complexities of diabetic cardiomyopathy: lessons from patients and animal models,” Current Diabetes Reports, vol. 8, no. 3, pp. 243–248, 2008.

[24] I. Jalal, D. Stein, D. Balis, S. M. Grundy, B. Adams-Huet, and S. Devaraj, “Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels,” Circulation, vol. 103, no. 15, pp. 1933–1935, 2001.

[25] N. A. Turner, R. S. Mughal, P. Warburton, D. J. O’Regan, S. G. Ball, and K. E. Porter, “Mechanism of TNF-α-induced IL-1α, IL-1β and IL-6 expression in human cardiac fibroblasts: Effects of statins and thiazolidinediones,” Cardiovascular Research, vol. 76, no. 1, pp. 81–90, 2007.

[26] A. Schmehel, M. Grimm, A. El-Armouche et al., “Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects,” Cardiovascular Research, vol. 82, no. 1, pp. 100–106, 2009.

[27] C. Kirsch, G. P. Eckert, and W. E. Mueller, “Statin effects on cholesterol micro-domains in brain plasma membranes,” Biochemical Pharmacology, vol. 65, no. 5, pp. 843–856, 2003.

[28] G. di Salvo, P. Caso, R. Lo Piccolo et al., “Atrial myocardial deformation properties predict maintenance of sinus rhythm after external cardioversion of recent-onset lone atrial fibrillation: a color Doppler myocardial imaging and transthoracic and transesophageal echocardiographic study,” Circulation, vol. 112, no. 3, pp. 387–395, 2005.

[29] C. Yu, Q. Wang, C. Lau et al., “Reversible Impairment of Left and Right Ventricular Systolic and Diastolic Function During Short-Lasting Atrial Fibrillation in Patients with an Implantable Atrial Defibrillator: A Tissue Doppler Imaging Study,” Pacing and Clinical Electrophysiology, vol. 24, no. 6, pp. 979–988, 2001.

[30] M. M. Redfield, G. Neal Kay, L. S. Jenkins et al., “Tachycardia-related cardiomyopathy: A common cause of ventricular dys-function in patients with atrial fibrillation referred for atrioventricular ablation,” Mayo Clinic Proceedings, vol. 75, no. 8, pp. 790–795, 2000.

[31] O. T. Gurevitz, N. M. Ammask, J. F. Malouf et al., “Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter,” American Heart Journal, vol. 149, no. 2, pp. 316–321, 2005.